Age-based disparities in statin use for primary prevention in US adults : National Health and Nutrition Examination Surveys 2013-2020
Copyright © 2023 National Lipid Association. Published by Elsevier Inc. All rights reserved..
Statin use among younger adults at high atherosclerotic cardiovascular disease (ASCVD) risk compared with older adults at the same risk is unclear. We determined prevalent statin use by 10-year ASCVD risk and age among US participants aged 40-75 eligible for risk-indicated primary prevention statins from the 2013-2020 National Health and Nutrition Examination Survey cycles. Among 3,503 participants, statin use by ASCVD risk (5-<7.5%, 7.5-<20%, and ≥20%) was 9.4%, 9.0%, and 12.2% among those age 40-54 compared to 22.0%, 23.9%, and 14.3% among adults 55-64 years and 39.3%, 33.6%, and 38.1% age 65-75 years. After adjusting for sociodemographic and healthcare access, the prevalence ratio (vs. 65-75 years) for statin use among adults with an ASCVD risk of 7.5-<20% age 40-54 years was 0.40 (95% confidence interval [CI] 0.39,0.41) and 0.87 (95% CI 0.87,0.88) for adults 55-64 years. Among high ASCVD-risk adults aged 40-75 years, primary prevention statin use was lower among adults <65 years despite similar ASCVD risk as older adults.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of clinical lipidology - 17(2023), 5 vom: 08. Sept., Seite 688-693 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheutlin, Alexander R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Age |
|---|
| Anmerkungen: |
Date Completed 01.12.2023 Date Revised 10.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacl.2023.08.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360979351 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360979351 | ||
| 003 | DE-627 | ||
| 005 | 20240114233343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacl.2023.08.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1255.xml |
| 035 | |a (DE-627)NLM360979351 | ||
| 035 | |a (NLM)37599197 | ||
| 035 | |a (PII)S1933-2874(23)00250-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheutlin, Alexander R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Age-based disparities in statin use for primary prevention in US adults |b National Health and Nutrition Examination Surveys 2013-2020 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2023 | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 National Lipid Association. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Statin use among younger adults at high atherosclerotic cardiovascular disease (ASCVD) risk compared with older adults at the same risk is unclear. We determined prevalent statin use by 10-year ASCVD risk and age among US participants aged 40-75 eligible for risk-indicated primary prevention statins from the 2013-2020 National Health and Nutrition Examination Survey cycles. Among 3,503 participants, statin use by ASCVD risk (5-<7.5%, 7.5-<20%, and ≥20%) was 9.4%, 9.0%, and 12.2% among those age 40-54 compared to 22.0%, 23.9%, and 14.3% among adults 55-64 years and 39.3%, 33.6%, and 38.1% age 65-75 years. After adjusting for sociodemographic and healthcare access, the prevalence ratio (vs. 65-75 years) for statin use among adults with an ASCVD risk of 7.5-<20% age 40-54 years was 0.40 (95% confidence interval [CI] 0.39,0.41) and 0.87 (95% CI 0.87,0.88) for adults 55-64 years. Among high ASCVD-risk adults aged 40-75 years, primary prevention statin use was lower among adults <65 years despite similar ASCVD risk as older adults | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Age | |
| 650 | 4 | |a Cardiovascular risk | |
| 650 | 4 | |a Healthcare disparities | |
| 650 | 4 | |a Metabolic syndrome | |
| 650 | 4 | |a Statin | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Jacobs, Joshua A |e verfasserin |4 aut | |
| 700 | 1 | |a Derington, Catherine G |e verfasserin |4 aut | |
| 700 | 1 | |a Chaitoff, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Navar, Ann Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Bress, Adam P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical lipidology |d 2007 |g 17(2023), 5 vom: 08. Sept., Seite 688-693 |w (DE-627)NLM175693773 |x 1933-2874 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:5 |g day:08 |g month:09 |g pages:688-693 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacl.2023.08.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 5 |b 08 |c 09 |h 688-693 | ||